Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript

Page 4 of 4

We’re the only folks that have the three presentations. We’re positioned for market’s stability and sustainability as we go forward now with pegfilgrastim and that’s where we want to be.

Operator: [Operator Instructions] And I’m not showing any further questions. I would now like to turn the call back over to Denny Lanfear for any closing remarks.

Dennis Lanfear: Thank you, operator. And thank you all for joining us on our Q4 full-year 2023 call this afternoon. We’re pleased with our progress on all fronts to drive our sales higher, strictly control our expenses, reduce our debt and advance our pipeline. We are entering 2024 with strong upward momentum and a clear organizational focus on extending survival for patients with cancer. We look forward to seeing you all at the upcoming investor conferences and on our next call. Thank you.

Operator: Thank you for your participation. You may now disconnect.

Theresa LaVallee: Goodbye.

Follow Charming Shoppes Inc (NASDAQ:CHRS)

Page 4 of 4